This month on Synapse
Written by a team of Taylor Wessing's legal experts, The Treatment is designed to provide a high level overview of some of the most important issues to consider for any life sciences company seeking these opportunities by coming to Europe.
Session 2 of our 2019 biosimilars webinars series focuses on key factors decision makers need to be aware of when considering currently pending legislation.
Michael Washbrook provides an overview of the new SPC manufacturing waiver for export and stockpiling that will come into force on 1 July 2019.
Dr Anja Lunze explores the decision of the German Federal Supreme Court to refuse Sanofi’s request for a preliminary compulsory licence regarding Amgen’s patent relating to antigen binding proteins against PCSK9.
